On the one hand, CXCL9 is commonly known as a chemokine with anti-tumor properties that contribute to effective T cell responses and immune infiltration, and it can serve as a favorable prognostic marker in PDA [32,33,34]. Here, CXCL9 is linked to Patent ductus arteriosus.